Description in a few words:
Arven was founded in 2013 with the aim of producing high technology products. Arven aimed to exist in the fields of respiratory ilnesses and illnesses that require biotechnological products and shaped its studies with the principle of ‘foresight in respiration & biotechnology and safe treatment.’ We design technology for the future and we provide the future for human health.
Zafer Toksöz, Chairman
“Arven Pharmaceuticals succeeded in developing the first Turkish patented dry powder inhaler, "Sanohaler" as a result of long lastigng R&D activities, representing a significant milestone for the Turkish pharmaceutical industry.”
Arven has three different Production Departments:
1. Inhaler Production Department
1a. Two Blister Filling Machine
1b. Capsule Filling Machine
1c. Inhaler Device Assembly Machine
1d. Inhaler Final Assembly Machine
2. Biotechnology Production Department
2a. Microbial Production
· 50L Fermentor and all Purification equipment
· 200L and 1000L Bioreactors and all
· All equipment are using with Single Use
3. Sterile Filling Department
3a.1mL Syringe, 2R and 4R filling machine
Main product categories or therapies of focus
Arven is focusing on high technology products, dry powder inhalation products, and biopharmaceutical products as its main working groups.
Number of APIs produced
Arven is producing one Biosimilar API called Filgrastim.
Primary packaging production
Arven has different types of Primary packaging. These are:
· Blister filling
· Capsule filling
· Sterile filling
Arven uses 2D barcode system for serialization operations.
Total number of delivered boxes/year
Total number of delivered boxes per year is 1.2 million for Inhalation products. In addition, Arven has capacity for up to 5 million boxes per year.
Total number of delivered boxes per year is 100,000 for biosimilar product. Arven also has capacity up to 350,000 boxes per year for current product.
Biosimilar and Inhaler technology
In More Depth
Arven has Turkish Ministry of Health GMP certificate that is compliant with PICs regulations.
Growth rate: 20.8%
Arven was the first company to produce a biosimilar product from cell to finished product in Turkey and the first company to have patent protected Multi-Unit dose Dry Powder inhaler in Turkey.